Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.50 |
| ▸ | TNNC1 | P63316 | 6/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.50 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.50 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9776023 | 0.77 | SIGMAR1 (0.41) | S1PR1TNNC1S1PR4S1PR3S1PR5 | |
| SCHEMBL9776134 | 0.77 | SIGMAR1 (0.41) | S1PR1TNNC1S1PR4S1PR3S1PR5 | |
| SCHEMBL9776156 | 0.77 | ARG1 (0.47) | SIGMAR1FDPS | |
| SCHEMBL28979397 | 0.75 | SIGMAR1 (0.44) | SIGMAR1FDPS | |
| SCHEMBL9422769 | 0.74 | FDPS (0.47) | SIGMAR1FDPS | |
| SCHEMBL9130780 | 0.74 | FDPS (0.47) | SIGMAR1FDPS | |
| SCHEMBL141241 | 0.74 | FDPS (0.47) | SIGMAR1FDPS | |
| SCHEMBL2212796 | 0.73 | TNNC1 (0.49) | S1PR1TNNC1S1PR4S1PR3S1PR5 | |
| SCHEMBL8499516 | 0.73 | S1PR1 (0.87) | S1PR1TNNC1S1PR4S1PR3S1PR5 | |
| SCHEMBL8499357 | 0.73 | S1PR1 (0.87) | S1PR1TNNC1S1PR4S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4994617-A | Analgesics | JOUVEINAL S.A. (FR) | 1991-02-19 | — | — | US | claimed |
| EP-0237366-A1 | Amino alcohols, process for their preparation and their applications, in particular for therepeutical use | JOUVEINAL S.A. (FR) | 1987-09-16 | — | — | EP | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | CombinatoRx, (Singapore) Pte. Ltd. | 2010-04-01 | — | — | US | disclosed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080287406-A1 | Compositions and methods for treating medical conditions | ZALICUS INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080280862-A1 | Methods, compositions, and kits for the treatment of pain | COMBINATORX, INCORPORATED | 2008-11-13 | — | — | US | disclosed |
| WO-2008133884-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20040229849-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | COMBINATORX, INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| US-20040220153-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | COMBINATORX, INCORPORATED | 2004-11-04 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004030618-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX, INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
| US-4994617-A | Analgesics | JOUVEINAL S.A. (FR) | 1991-02-19 | — | — | US | disclosed |
| EP-0237366-B1 | AMINO ALCOHOLS, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATIONS, IN PARTICULAR FOR THEREPEUTICAL USE | JOUVEINAL S.A. (FR) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280862-A1 | Methods, compositions, and kits for the treatment of pain | ACHE, MPO, P2RX3 | S1PR1 3173/4885TNNC1 58/4885S1PR4 3054/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | S1PR1 807/4885TNNC1 1191/4885S1PR4 941/4885 |
| US-20040220153-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | TNF, IL5, IL6 | S1PR1 592/4885TNNC1 2062/4885S1PR4 783/4885 |
| US-20080287406-A1 | Compositions and methods for treating medical conditions | S100B, S100P, S100A6 | S1PR1 1189/4885TNNC1 231/4885S1PR4 1454/4885 |
| US-20040229849-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | TNF, IL5, IL6 | S1PR1 592/4885TNNC1 2062/4885S1PR4 783/4885 |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | IFNG, IL5, HAVCR2 | S1PR1 2070/4885TNNC1 207/4885S1PR4 2358/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | S1PR1 923/4885TNNC1 2585/4885S1PR4 972/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | S1PR1 923/4885TNNC1 2585/4885S1PR4 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.